Amplification of a gene encoding a p53-associated protein in human sarcomas

Cited by (1,001)

Items 401–500 of 1,001

1. Clinicopathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas
   Ademar Takahama, Fábio de Abreu Alves, Clóvis Antônio Lopes Pinto, André Lopes Carvalho, Luiz Paulo Kowalski, Márcio Ajudarte Lopes · 2003 · Oral Oncology
2. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
   Stephanie P. Dowell, P. Wilson, Nawal W. Derias, David Philip Lane, P. A. Hall · 1994 · PubMed
3. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53
   Magdalena Wienken, Antje Dickmanns, Alice Nemajerová, Daniela Kramer, Zeynab Najafova, Miriam Weiss, Oleksandra Karpiuk, Moustapha S Kassem, Yanping Zhang, Guillermina Lozano et al. · 2015 · Molecular Cell
4. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status
   Alfonso Quintás‐Cardama, C Hu, Amina Ann Qutub, Y H Qiu, Xuesong Zhang, Sean M. Post, Nianziang Zhang, Kevin R. Coombes, Steven Mitchell Kornblau · 2016 · Leukemia
5. Role of two upstream open reading frames in the translational control of oncogene mdm2
   Cheryl Y. Brown, Gregory J. Mize, Mario Javier Pineda, Donna L. George, David Morris · 1999 · Oncogene
6. Transcriptional Regulation of the mdm2 Oncogene by p53 Requires TRRAP Acetyltransferase Complexes
   Penny G. Ard, Chandrima Chatterjee, Sudeesha Kunjibettu, Leon R. Adside, Lisa E. Gralinski, Steven B. McMahon · 2002 · Molecular and Cellular Biology
7. The Molecular Biology of Ependymomas
   Ronald L. Hamilton, Ian F. Pollack · 1997 · Brain Pathology
8. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope
   Atif Zafar, Wei Wang, Gang Liu, Wa Xian, Frank McKeon, Jia Zhou, Ruiwen Zhang · 2020 · Cancer Letters
9. Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors.
   V.V.V.S. Murty, Jane Houldsworth, S Baldwin, Victor E. Reuter, Willi H. Hunziker, Peter Besmer, George J. Bosl, R. S. K. CHAGANTI · 1992 · Proceedings of the National Academy of Sciences
10. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Monika Phelps, Matthew Darley, John N Primrose, Jeremy P. Blaydes · 2003 · PubMed
11. Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors
    Béatrice Eymin, Sylvie Gazzéri, Christian Brambilla, Elisabeth M. Brambilla · 2002 · Oncogene
12. Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner
    Ted R. Hupp, David Philip Lane · 1995 · Journal of Biological Chemistry
13. MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification
    Duk‐Hwa Kwon, Gwang Hyeon Eom, Jeong Hyeon Ko, Sera Shin, Hosouk Joung, Nakwon Choe, Yoon Seok Nam, Hyun-Ki Min, Taewon Kook, Somy Yoon et al. · 2016 · Nature Communications
14. Ancient Genomes, Wise Bodies, Unhealthy People: Limits of a Genetic Paradigm in Biology and Medicine
    Richard C. Strohman · 1993 · Perspectives in biology and medicine
15. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers
    Ruiying Zhao, Sai‐Ching J. Yeung, Jian Chen, Tomoo Iwakuma, Chun‐Hui Su, Bo Chen, Changju Qu, Fanmao Zhang, You‐Tzung Chen, Yu Lin et al. · 2011 · Journal of Clinical Investigation
16. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.
    Florencia Bullrich, Timothy K. MacLachlan, Nianli Sang, Teresa Druck, Maria Luisa Veronese, Steven L. Allen, Nicholas Chiorazzi, Andrew Koff, Kay Heubner, Carlo Maria Croce · 1995 · PubMed
17. p53 binds to the TATA-binding protein-TATA complex
    Daniel W. Martin, R.M. Muñoz, Mark A. Subler, Sumitra Deb · 1993 · Journal of Biological Chemistry
18. Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
    Vivien Landré, Barak Rotblat, Sonia Melino, Francesca Bernassola, Gerry Melino · 2014 · Oncotarget
19. Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration
    Andrew W. Burr, Kieran Toole, Claire Chapman, Julie E. Hines, Alastair D. Burt · 1998 · The Journal of Pathology
20. MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies
    Zhibin Hu, Guangfu Jin, Lu Wang, Feng Chen, Xinru Wang, Hongbing Shen · 2007 · Cancer Epidemiology Biomarkers & Prevention
21. Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma
    Antonio Domenico Procopio, Luigi Strizzi, Giovina Vianale, Pier‐Giacomo Betta, Riccardo Puntoni, Vincenzo Fontana, Gianfranco Tassi, Francesco Gareri, Luciano Mutti · 2000 · Genes Chromosomes and Cancer
22. Genotoxic Stress Induces Coordinately Regulated Alternative Splicing of the p53 Modulators MDM2 and MDM4
    Dawn S. Chandler, Ravi Kumar Singh, Lisa C. Caldwell, Jaquelyn L. Bitler, Guillermina Lozano · 2006 · Cancer Research
23. Role of p53 in Apoptosis
    Christine E. Canman, Michael B. Kastan · 1997 · Advances in pharmacology
24. Tumor suppressor genes and related molecules in leiomyosarcoma.
    Angelo Paolo Dei Tos, Roberta Maestro, Claudio Doglioni, Sara Piccinin, Duilio Delia Libera, Mauro Boiocchi, Christopher D.�M. Fletcher · 1996 · Europe PMC (PubMed Central)
25. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations
    Raquel Villuendas, MA Piris, P Algara, Margarita Sánchez‐Beato, L Sánchez‐Verde, JC Martinez, JL Orradre, P García, Clarissa Guadalupe Armenta López, P Martinez · 1993 · Blood
26. Genome-wide reconstruction of complex structural variants using read clouds
    Noah Spies, Ziming Weng, Alex Bishara, Jennifer McDaniel, David Catoe, Justin M. Zook, Marc Salit, Robert B. West, Serafim Batzoglou, Arend Sidow · 2017 · Nature Methods
27. Analysis of Genomic Alterations in Sporadic Adrenocortical Lesions
    Jianming Zhao, Ernst‐Jan M. Speel, Seraina Muletta-Feurer, Katrin Rütimann, Parvin Saremaslani, Jürgen Roth, Philipp U. Heitz, Paul Komminoth · 1999 · American Journal Of Pathology
28. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type
    Carla B. J. Vos, Natalja T. ter Haar, Carla Rosenberg, Johannes L. Peterse, A.M. Cleton-Jansen, Cees J. Cornelisse, Marc J. van de Vijver · 1999 · British Journal of Cancer
29. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
    Arushi Khurana, Danielle A. Shafer · 2019 · OncoTargets and Therapy
30. The Phosphatase MKP1 Is a Transcriptional Target of p53 Involved in Cell Cycle Regulation
    Maoxiang Li, Jun-Ying Zhou, Yubin Ge, Larry H. Matherly, Gen Sheng Wu · 2003 · Journal of Biological Chemistry
31. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13–15: A combined cytogenetic and comparative genomic hybridization study
    Jadwiga Szymanska, Nils Mandahl, Fredrik Mertens, Maija Tarkkanen, Erkki O. Karaharju, Sakari Knuutila · 1996 · Genes Chromosomes and Cancer
32. mdm2 gene alterations and mdm2 protein expression in breast carcinomas
    Antonio Marchetti, Fiamma Buttitta, Salvatore Girlando, Paolo Dalla Palma, Silvia Pellegrini, Paolo Fina, Claudio Doglioni, Generoso Bevilacqua, Mattia Barbareschi · 1995 · The Journal of Pathology
33. Abnormal expression of MDM-2 in breast carcinomas
    Carlos Bueso-Ramos, Taghi Manshouri, Mohammad A. Haidar, Yun Sheng Yang, P McCown, Nelson G. Ordóǹez, Armand B. Glassman, Nour Sneige, Maher X. Albitar · 1996 · Breast Cancer Research and Treatment
34. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Robert Evan Reiter, Patrick Anglard, S. Liu, James R. Gnarra, William Marston Linehan · 1993 · PubMed
35. Abnormal Expression of MDM2 in Prostate Carcinoma
    Kátia Ramos Moreira Leite, Marcello Fabiano de Franco, Miguel Srougi, Luciano Nesrallah, Adriano Nesrallah, Ruy Geraldo Bevilacqua, Elaine Darini, Claudia M. Carvalho, Maria Ines Meirelles, Isaque Santana et al. · 2001 · Modern Pathology
36. Deletion of RBExons 24 and 25 Causes Low-Penetrance Retinoblastoma
    Rod Bremner, D. Du, Mary Connolly-Wilson, Peter J. Bridge, K. Farid Ahmad, Homa Mostachfi, Dianne Rushlow, James M. Dunn, Brenda L. Gallie · 1997 · The American Journal of Human Genetics
37. Chromosome instability in cancer: how, when, and why?
    David Gisselsson · 2003 · Advances in cancer research
38. Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells
    Mitsuru Miyachi, Naoki Kakazu, Shigeki Yagyu, Yoshiki Katsumi, Satoko Tsubai-Shimizu, Ken Kikuchi, Kunihiko Tsuchiya, Tomoko Iehara, Hajime Hosoi · 2009 · Clinical Cancer Research
39. Alterations of the p15, p16, and p18 genes in osteosarcoma
    Carl W. Miller, A. Aslo, Moray J. Campbell, Norihiko Kawamata, Beatrice C. Lampkin, Harold Phillip Koeffler · 1996 · Cancer Genetics and Cytogenetics
40. In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis
    Dilara Islam, BÉLA VERESS, Pradip Kumar Bardhan, Alf A. Lindberg, Birger Christensson · 1997 · Infection and Immunity
41. MDM2 Enhances the Function of Estrogen Receptor α in Human Breast Cancer Cells
    Shigehira Saji, Naoki Okumura, Hidetaka Eguchi, Shigeru Nakashima, Akio Suzuki, Masakazu Toi, Yoshinori Nozawa, Shigetoyo Saji, Shin‐ichi Hayashi · 2001 · Biochemical and Biophysical Research Communications
42. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas
    Toshifumi Ozaki, Karl‐Ludwig Schaefer, Daniel Wai, Horst Buerger, Silke Flege, Norbert J. Lindner, Matthias Kevric, Raihanatou Ina Diallo, Ágnes Bánkfalvi, Christian Brinkschmidt et al. · 2002 · International Journal of Cancer
43. PTEN Regulates Mdm2 Expression through the P1 Promoter
    Chun-Ju Chang, Daniel J. Freeman, Hong Wu · 2004 · Journal of Biological Chemistry
44. Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases
    Péter Erhardt, K J Tomaselli, Geoffrey M. Cooper · 1997 · Journal of Biological Chemistry
45. Analysis of p53 Gene Mutations in Keloids Using Polymerase Chain Reaction–Based Single-Strand Conformational Polymorphism and DNA Sequencing
    Ghassan M. Saed, Daniel Alexander Ladin, Jennifer Olson, Xuefei Han, Zizheng Hou, David P. Fivenson · 1998 · Archives of Dermatology
46. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
    Sharmila Patel, Mark R. Player · 2008 · Expert Opinion on Investigational Drugs
47. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
    Mikael S. Lindström, Ulf Klangby, Klas G. Wiman · 2001 · Oncogene
48. Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase
    Ambrus Tóth, Philip Nickson, Liu Liang Qin, Péter Erhardt · 2005 · Journal of Biological Chemistry
49. An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
    Steinman, Heather A., Burstein, Ezra, Lengner, Christopher, Gosselin, Joseph, Pihan, German, Duckett, Colin S., Jones, Stephen N. · 2004 · Journal of Biological Chemistry
50. Fourier analysis and systems identification of the p53 feedback loop
    Naama Geva‐Zatorsky, Erez Dekel, Eric Batchelor, Galit Lahav, Uri S. Alon · 2010 · Proceedings of the National Academy of Sciences
51. MDM2’s social network
    Robin Fåhræus, Vanesa Olivares‐Illana · 2013 · Oncogene
52. MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells
    Gerrard K. H. Teoh, Mitsuyoshi Urashima, Atsushi Ogata, Dharminder Chauhan, James A. DeCaprio, Steven Peter Treon, Robert L Schlossman, Kenneth Carl Anderson · 1997 · Blood
53. Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer
    Wenrui Duan, Li Gao, Lawrence J. Druhan, Wei‐Guo Zhu, Carl Morrison, Gregory A. Otterson, Miguel Angel Villalona-Calero · 2004 · JNCI Journal of the National Cancer Institute
54. Cell cycle regulatory functions of the human oncoprotein MDM2.
    Swati Palit Deb · 2003 · PubMed
55. Human genome project: Italian contribution. Future directions
    Renato Dulbecco · 1997 · Journal of Cellular Physiology
56. MDM2 and CDK4 gene amplification in Ewing's sarcoma
    Marc Ladanyi, Ronald Lewis, Suresh C. Jhanwar, William L. Gerald, Andrew G. Huvos, John H. Healey · 1995 · The Journal of Pathology
57. The structure of an MDM2–Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant
    Burcu Anil, Christiane Riedinger, Jane Endicott, Martin E. M. Noble · 2013 · Acta Crystallographica Section D Biological Crystallography
58. Regulation of the p14ARF-Mdm2-p53 pathway: An overview in breast cancer
    Anshu Agrawal, Jianhui Yang, Richard F. Murphy, Devendra K. Agrawal · 2006 · Experimental and Molecular Pathology
59. Defective Osteogenic Differentiation in the Development of Osteosarcoma
    Eric R. Wagner, Gaurav Aman Luther, Gaohui Zhu, Qing Luo, Qiong Shi, Stephanie H. Kim, Jian‐Li Gao, Enyi Huang, Yanhong Gao, Ke Yang et al. · 2011 · Sarcoma
60. Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
    Elias Drakos, Athanasios X Thomaides, Leonard Jeffrey Medeiros, Li Jiang, Vasiliki Leventaki, Marina Y Konopleva, Michael Andreeff, George Z. Rassidakis · 2007 · Clinical Cancer Research
61. p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53
    Lihong Chen, Hang Hubert Yin, Bilal Farooqi, Saı̈d M. Sebti, Andrew D. Hamilton, Jiandong Chen · 2005 · Molecular Cancer Therapeutics
62. Nuclear degradation of p53 occurs during down‐regulation of the p53 response after DNA damage
    Troy R. Shirangi, Alex Zaika, Ute Martha Moll · 2002 · The FASEB Journal
63. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival
    Nikolai G. Rainov, Karl-Ulrich Dobberstein, Hannes Bahn, Hans-Jürgen Holzhausen, Christine Lautenschläger, Volkmar Heidecke, Winfried L. Burkert · 1997 · Journal of Neuro-Oncology
64. Unleashing the power of p53: lessons from mice and men: Figure 1.
    Masha V. Poyurovsky, Carol L. Prives · 2006 · Genes & Development
65. p53-Independent Effects of Mdm2
    Stephen Bohlman, James J. Manfredi · 2014 · Sub-cellular biochemistry/Subcellular biochemistry
66. Aging and cancer: The role of stromal interactions with epithelial cells
    Clifford A. Rinehart, Vincent R. Torti · 1997 · Molecular Carcinogenesis
67. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors
    Mef Christina Nilbert, Felix Mitelman, Nils Mandahl, Anders Rydholm, Helena Willén · 1994 · Genes Chromosomes and Cancer
68. Mdm2 in the Response to Radiation
    Mary Ellen Perry · 2004 · Molecular Cancer Research
69. A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2
    Mark T. Boyd, Nikolina Vlatković, Dale S. Haines · 2000 · Journal of Biological Chemistry
70. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
    Abha Saxena, W. Craig Clark, J T Robertson, Barbara L. Ikejiri, Edward H. Oldfield, I U Ali · 1992 · PubMed
71. Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction
    Ian Robert Hardcastle, Shafiq Uddin Ahmed, Helen Atkins, Hilary Calvert, Nicola J. Curtin, Gillian Farnie, Bernard T. Golding, Roger J. Griffin, Sabrina Guyenne, Claire Hutton et al. · 2005 · Bioorganic & Medicinal Chemistry Letters
72. Ubiquitin, E6-AP, and Their Role in p53 Inactivation
    Martin Scheffner · 1998 · Pharmacology & Therapeutics
73. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
    Wenge Lu, Radhika R. Pochampally, Lihong Chen, Mullika Traidej Chomnawang, Yiliang Wang, Jiandong Chen · 2000 · Oncogene
74. The interplay of NR4A receptors and the oncogene–tumor suppressor networks in cancer
    Jordan A. Beard, Alexa Tenga, Taosheng Chen · 2014 · Cellular Signalling
75. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
    Bernard Leroy, Mandy L. Ballinger, Fanny Baran‐Marszak, Gareth L. Bond, Antony W. Braithwaite, Nicole Concin, Lawrence A. Donehower, Wafik S. El‐Deiry, Pierre Fenaux, Gianluca Gaïdano et al. · 2017 · Cancer Research
76. The p53 and mdm‐2 genes in human testicular germ‐cell tumors
    Guy F. RIOU, Michel Barrois, Sandrine Prost, Marie Josée Terrier, Christine Théodore, Arnold J. Levine · 1995 · Molecular Carcinogenesis
77. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger
    Michael Nicholas Boddy, Paul S. Freemont, Katherine L. B. Borden · 1994 · Trends in Biochemical Sciences
78. Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
    Yujun Zhao, Denzil Bernard, Shaomeng Wang · 2013 · Biodiscovery
79. Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.
    P. Ragazzini, Gabriella Gamberi, Laura Pazzaglia, Massimo Serra, Giovanna Magagnoli, Francesca Ponticelli, Cristina Ferrari, Cristina Ghinelli, Marco Alberghini, Francesco Bertoni et al. · 2004 · PubMed
80. A Nonpeptidic Sulfonamide Inhibits the p53−mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells
    Peter S. Galatin, Donald J. Abraham · 2004 · Journal of Medicinal Chemistry
81. A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein
    Deborah A. Freedman, Charles B. Epstein, Judith C. Roth, Arnold J. Levine · 1997 · Molecular Medicine
82. The relationship between serum p53 autoantibodies and characteristics of human breast cancer
    Boyd Mudenda, JA Green, B. Green, J. Jenkins, Lindsay B. Robertson, Marina Tarunina, Sam Leinster · 1994 · British Journal of Cancer
83. Cytogenetic findings in 33 osteosarcomas
    Fredrik Mertens, Nils Mandahl, Charlotte Örndal, Bo Baldetorp, Henrik C. F. Bauer, Anders Rydholm, Thomas Wiebe, Helena Willén, Måns Åkerman, Sverre Heim et al. · 1993 · International Journal of Cancer
84. Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression
    Limin Zhu, Madonna M. McManus, Dennis P.M. Hughes · 2013 · Frontiers in Oncology
85. Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
    Alessia Bertamino, Maria Soprano, Simona Musella, Maria Rosaria Rusciano, Marina Sala, Ermelinda Vernieri, Veronica Di Sarno, Antonio Limatola, Alfonso Carotenuto, Sandro Cosconati et al. · 2013 · Journal of Medicinal Chemistry
86. Label-free impedimetric immunosensor for ultrasensitive detection of cancer marker Murine double minute 2 in brain tissue
    Reda Elshafey, Chaker Tlili, Abedelnasser Abulrob, Ana C. Tavares, Mohammed M. Zourob · 2012 · Biosensors and Bioelectronics
87. The p53 Tumor Suppressor Protein Does Not Regulate Expression of Its Own Inhibitor, MDM2, Except under Conditions of Stress
    Susan M. Mendrysa, Mary Ellen Perry · 2000 · Molecular and Cellular Biology
88. Tumor Suppressor p53 Mutations and Breast Cancer: A Critical Analysis
    Michelle A. Ozbun, Janet S. Butel · 1995 · Advances in cancer research
89. Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer?
    Bora Uyar, Robert J. Weatheritt, Holger Dinkel, Norman E. Davey, Toby J. Gibson · 2014 · Molecular BioSystems
90. NAD+ Modulates p53 DNA Binding Specificity and Function
    Kevin G. McLure, Masatoshi Takagi, Michael B. Kastan · 2004 · Molecular and Cellular Biology
91. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia
    Maohua Zhou, Liqun Gu, Thomas C. Abshire, AC Homans, Amy Louise Billett, AM Yeager, Harry W. Findley · 2000 · Leukemia
92. NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway
    Arundhati Jana, Nancy L. Krett, Grace Guzman, Ahmer Khalid, Özkan Özden, Jonas J. Staudacher, Jessica I. Bauer, Ron Baik, Timothy P. Carroll, Cemal Yazıcı et al. · 2017 · Oncotarget
93. Transforming growth factor-? responsiveness inDPC4/SMAD4-null cancer cells
    Jia Le Dai, Mieke E. M. Schutte, Ravi K. Bansal, Robb E. Wilentz, Avrahom Y. Sugar, Scott E. Kern · 1999 · Molecular Carcinogenesis
94. The promise of cancer genetics
    Daniel A. Haber, Eric R. Fearon · 1998 · The Lancet
95. Adenovirus-mediated p53 Gene Therapy for Human Gliomas
    Frederick F. Lang, W.K. Alfred Yung, Raymond A. Sawaya, Philip J. Tofilon · 1999 · Neurosurgery
96. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes
    Parker, Mufti · 1998 · British Journal of Haematology
97. An mTORC1-Mdm2-Drosha Axis for miRNA Biogenesis in Response to Glucose- and Amino Acid-Deprivation
    Peiying Ye, Yu Liu, Chong Chen, Fei Tang, Qi Wu, Xiang Wang, Chang-Gong Liu, Xiuping Liu, Runhua Liu, Yang Liu et al. · 2015 · Molecular Cell
98. A New Twist in the Feedback Loop: Stress-Activated MDM2 Destabilization is Required for p53 Activation
    Jayne M. Stommel, Geoffrey M. Wahl · 2005 · Cell Cycle
99. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A gene
    Helena Carén, Jennie Erichsen, Linda Olsson, Charlotta Enerbäck, Rose‐Marie Sjöberg, Jonas Abrahamsson, Per Kogner, Tommy Martinsson · 2008 · BMC Genomics
100. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2
     Stephen N. Jones, Arthur Sands, Amy R. Hancock, Hannes S. Vogel, Lawrence A. Donehower, Steven P. Linke, Geoffrey M. Wahl, Allan Bradley · 1996 · Proceedings of the National Academy of Sciences